According to a report in Reuters, the Federal Trade Commission (FTC) is investigating the pharmaceutical company Shire for possible agreements delaying the generic marketing of Adderall XR, a drug used for attention deficit disorder. Last week the FTC released a report about 33 different agreements in which generic drug manufacturers agreed to delay marketing drugs coming off patent. The availability of generics is estimated to reduce the cost of drugs by as much as 90 percent and cuts into the profits of patented medication. The FDA called this "anti-competitive."
Consider This
by Phyllis Vine
MIWatch.org on Facebook
Relevant Sites
- Visit the Illinois neurology department of Northshore
Featured Videos
Most Popular
MIWatch Archives
This site complies with the HONcode standard for trustworthy health information:
verify here.
